Professor Michael Boyer AM is a Clinical Professor within the Central Clinical School of the University of Sydney Faculty of Medicine and Health, where he holds the Kam Ling Barbara Lo Chair in Lung and Thoracic Cancer. He earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) from the University of Sydney, a PhD in Cell Biology from the University of Toronto, and is a Fellow of the Royal Australasian College of Physicians (FRACP). As a medical oncologist with over 20 years of experience specializing in thoracic and head and neck cancers, Boyer previously served as Director of the Sydney Cancer Centre and Area Director of Cancer Services for the Sydney South West Area Health Service. Since 2011, he has been Chief Clinical Officer at Chris O’Brien Lifehouse, advancing to Chief Executive Officer and Board member in 2023, while also holding the position of Conjoint Chair of Medical Oncology (Thoracic Oncology).

In 2010, Professor Boyer was appointed a Member of the Order of Australia (AM) for service to medicine as an educator, clinical trials researcher, and leader in developing integrated care facilities for cancer patients. His research centers on clinical trials evaluating new anticancer drugs for lung cancer, including immunotherapy and targeted therapies for non-small cell lung cancer (NSCLC), EGFR mutations, malignant pleural mesothelioma, and head and neck cancers. Key publications include 'Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial' (2016), 'Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial' (2017), and 'Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations' (2013), contributing to over 18,000 citations. Boyer's leadership has significantly influenced thoracic oncology through innovative clinical research and integrated care models.

Professional Email: Michael.Boyer@lh.org.au